Protocol Ledger

NCT07365319 · Phase II/III · RECRUITING

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Interventional Phase II/III clinical trial protocol NCT07365319 sponsored by Eikon Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-15 Enrollment: 750 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07365319
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)750 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07365319
Protocol FieldVerified Registry Value
NCT IdentifierNCT07365319
Consolidated Lead SponsorEikon Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment750 participants (ESTIMATED)
Registered Start Date2026-06-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07365319
Hospital Research SiteLocationSite Profile
OSF Saint Francis Medical CenterPeoria, ILOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI